Samuel Gan

Prof. Dr. Samuel Gan

College of Science, Technology, and Mathematics, Wenzhou-Kean University, Wenzhou, Zhejiang, China
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
WCWeng-Tat Chan
Weng-Tat Chan
CVChandra S. Verma
Chandra S. Verma
DLDavid Lane
David Lane
SGSamuel Gan
Samuel Gan
DNA manipulation routinely requires competent bacteria that can be made using one of numerous methods. To determine the best methods, we compared four commonly used chemical methods (DMSO, MgCl2–CaCl2, CaCl2 and Hanahan's methods) on frequently used Escherichia coli (E. coli) strains: DH5α, XL-1 Blue, SCS110, JM109, TOP10 and BL21-(DE3)-PLysS. Hanahan's method was found to be most effective for DH5α, XL-1 Blue and JM109 strains (P<0.05), whilst the CaCl2 method was best for SCS110, TOP10 and BL21 strains (P<0.05). The use of SOB (super optimal broth) over LB [Luria–Bertani (broth)] growth media was found to enhance the competency of XL-1 Blue (P<0.05), dampened JM109′s competency (P0.05). We found no significant differences between using 45 or 90 s heat shock across all the six strains (P>0.05). Through further optimization by means of concentrating the aliquots, we were able to get further increases in transformation efficiencies. Based on the optimized parameters and methods, these common laboratory E. coli strains attained high levels of TrE (transformation efficiency), thus facilitating the production of highly efficient and cost-effective competent bacteria.

22 October 2008 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
PKPanagiotis Karagiannis
Panagiotis Karagiannis
JSJosef Singer
Josef Singer
JHJames Hunt
James Hunt
SGSamuel Gan
Samuel Gan
SRSarah M. Rudman
Sarah M. Rudman
Sophia N KaragiannisSophia N Karagiannis
Sophia N Karagiannis

1 January 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JTJoy En-Lin Tan
Joy En-Lin Tan
SWSiew-Cheng Wong
Siew-Cheng Wong
SGSamuel Gan
Samuel Gan
SXShengli Xu
Shengli Xu
KLKong-Peng Lam
Kong-Peng Lam
B lymphocytes lacking the adaptor protein B cell linker (BLNK) do not proliferate in response to B cell antigen receptor (BCR) engagement. We demonstrate here that BCR-activated BLNK− /− B cells fail to enter the cell cycle, and this is due to their inability to induce the expression of the cell cycle regulatory proteins such as cyclin D2 and cyclin-dependent kinase 4. BCR-stimulated BLNK− /− B cells also do not up-regulate the cell survival protein Bcl-xL, which may be necessary for the cells to complete the cell cycle. In addition, BLNK− /− B cells exhibit a high rate of spontaneous apoptosis in culture. Examination of the various BCR-activated signaling pathways in mouse BLNK− /− B cells reveals the intact activation of Akt and mitogen-activated protein kinases but the impaired activation of nuclear factor (NF)-κB that is known to regulate genes involved in cell proliferation and survival. The inability to activate NF-κB in BCR-stimulated BLNK− /− B cells is due to a failure to induce the degradation of the inhibitory κB protein. In all these aspects, BLNK− /− B cells resemble xid B cells that have a mutation in Bruton's tyrosine kinase (Btk). Recently, phospholipase C (PLC)-γ2 has also been demonstrated to be essential for NF-κB activation. Since BLNK has been shown separately to interact with both Btk and PLC-γ2, our finding of normal Btk but impaired PLC-γ2 activation in BCR-stimulated BLNK− /− B cells strongly suggests that BLNK orchestrates the formation of a Btk-PLC-γ2 signaling axis that regulates NF-κB activation. Taken together, the NF-κB activation defect may be sufficient to explain the similar defects in BCR-induced B cell proliferation and T cell-independent immune responses in BLNK− /−, Btk− /−, and PLC-γ2− /− mice.

20 September 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
ADAnthony M. Deacy
Anthony M. Deacy
SGSamuel Gan
Samuel Gan
JDJeremy P. Derrick
Jeremy P. Derrick
Superantigens are unconventional antigens which recognise immune receptors outside their usual recognition sites e.g. complementary determining regions (CDRs), to elicit a response within the target cell. T-cell superantigens crosslink T-cell receptors and MHC Class II molecules on antigen-presenting cells, leading to lymphocyte recruitment, induction of cytokine storms and T-cell anergy or apoptosis among many other effects. B-cell superantigens, on the other hand, bind immunoglobulins on B-cells, affecting opsonisation, IgG-mediated phagocytosis, and driving apoptosis. Here, through a review of the structural basis for recognition of immune receptors by superantigens, we show that their binding interfaces share specific physicochemical characteristics when compared with other protein-protein interaction complexes. Given that antibody-binding superantigens have been exploited extensively in industrial antibody purification, these observations could facilitate further protein engineering to optimize the use of superantigens in this and other areas of biotechnology.

15 January 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WLWai-Heng Lua
Wai-Heng Lua
WLWei-Li Ling
Wei-Li Ling
JYJoshua Yi Yeo
Joshua Yi Yeo
JPJun-Jie Poh
Jun-Jie Poh
DLDavid Lane
David Lane
SGSamuel Gan
Samuel Gan
Current therapeutic antibodies such as Trastuzumab, are typically of the blood circulatory IgG1 class (Cκ/ CHγ1). Due to the binding to Her2 also present on normal cell surfaces, side effects such as cardiac failure can sometimes be associated with such targeted therapy. Using antibody isotype swapping, it may be possible to reduce systemic circulation through increased tissue localization, thereby minimising unwanted side effects. However, the effects of such modifications have yet to be fully characterized, particularly with regards to their biophysical properties in antigen binding. To do this, we produced all light and heavy chain human isotypes/subtypes recombinant versions of Trastuzumab and Pertuzumab, and studied them with respect to recombinant production and Her2 binding. Our findings show that while the light chain constant region changes have no major effects on production or Her2 binding, some heavy chain isotypes, in particularly, IgM and IgD isotypes, can modulate antigen binding. This study thus provides the groundwork for such isotype modifications to be performed in the future to yield therapeutics of higher efficacy and efficiency.

7 June 2018 in Antibodies
Verified
Journal Article
Open access
PDF file
CSChinh Tran-To Su
Chinh Tran-To Su
WLWai Heng Lua
Wai Heng Lua
WLWei-Li Ling
Wei-Li Ling
SGSamuel Gan
Samuel Gan
Therapeutic antibodies have shifted the paradigm of disease treatments from small molecules to biologics, especially in cancer therapy. Despite the increasing number of antibody candidates, much remains unknown about the antibody and how its various regions interact. Recent findings showed that the antibody constant region can govern localization effects that are useful in reducing side effects due to systemic circulation by the commonly used IgG isotypes. Given their localized mucosal effects, IgA antibodies are increasingly promising therapeutic biologics. While the antibody Fc effector cell activity has been a focus point, recent research showed that the Fc could also influence antigen binding, challenging the conventional idea of region-specific antibody functions. To investigate this, we analysed the IgA antibody constant region and its distal effects on the antigen binding regions using recombinant Pertuzumab IgA1 and IgA2 variants. We found that mutations in the C-region reduced Her2 binding experimentally, and computational structural analysis showed that allosteric communications were highly dependent on the antibody hinge, providing strong evidence that we should consider antibodies as whole proteins rather than a sum of functional regions.